Scan how other corrections, debt clean ups and political crosswinds are playing out by lining up CoreCivic against the hand picked 32 resilient stocks with low risk scores in one view.
For CoreCivic, the core belief is that federal detention demand and related contracts stay supportive enough for high facility utilization, while the newer services arm such as Clinical Solutions Pharmacy builds into a second earnings pillar. The latest quarter showed very high reported profit due to the US$2.2b asset sale and strong ICE usage, but the slight full year guidance trim indicates that management sees some near term noise.
The key near term catalyst is execution on operations and services after the facility sale, especially keeping occupancy healthy while integrating Clinical Solutions Pharmacy. The biggest risk remains policy and funding exposure to ICE and other federal partners, now combined with a leadership transition and recent political change that has already pressured the stock price.
The most relevant update for that thesis is CoreCivic’s refined 2026 earnings guidance. Management now expects diluted EPS of US$15.42 to US$15.48 and net income of US$1.461b to US$1.467b, modestly below prior ranges. That adjustment came directly after a quarter where revenue and earnings from continuing operations were much higher than a year earlier.
For you as a shareholder or potential investor this matters because it helps clarify what portion of the Q3 surge is repeatable. The guidance band, together with the earlier raise to adjusted EPS and EBITDA expectations tied to stable populations and services growth, keeps the focus firmly on contract stability, policy risk and CoreCivic’s ability to translate its reshaped balance sheet into consistent operating performance.
Based on current analyst work, CoreCivic's narrative projects US$3.4b revenue and US$516.8m earnings by 2029. This assumes revenue growth of 11.6% per year and an increase in earnings of about US$388.9m from the current US$127.9m level.
Uncover why CoreCivic's fair value indicates a 48% potential upside to its current price that could narrow quickly.
One alternate narrative leans hard into CoreCivic’s idle capacity as a potential upside catalyst. Before this Q3 surprise, the most optimistic analysts were sketching out about US$3.6b of 2029 revenue and US$162.1m of earnings, backed by continued ICE demand and new state contracts. Those projections did not factor in this earnings print or the facility sale, so you may see those views shift as fresh forecasts roll in. Use this as a reminder that credible opinions can sit far apart and that your own judgement should weigh several competing stories before you commit capital.
Explore 2 other CoreCivic fair value estimates, including one that suggests an upside potential of as much as 48% from the current price!
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
Once you have a view on CoreCivic, it can help to zoom out and compare it with other listed businesses that match the kind of balance sheet strength, income focus, or valuation profile you are looking for. The Simply Wall St Screener can surface different shortlists that you can then filter further based on your own risk tolerance and return goals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com